Spruce Biosciences Q3 net loss $11.4M; cash $90.4M; enrollment milestones updated

SPRUCE BIOSCIENCES, INC.

2022-Q3 EPS reported -$1.49

Cash, cash equivalents and investments totaled $90.4M as of Sept 30, 2022.
Net loss for Q3 2022 was $11.4M, flat YoY; R&D expenses $8.8M vs $8.6M.
CAHmelia-203 approaching 50% enrollment; CAHmelia-204 surpassed 25% enrollment.
Appointed Saba Sile, M.D., as VP of Clinical Development from Horizon Therapeutics.
Topline results expected: PCOS trial H1 2023; CAHmelia-203 H2 2023; CAHmelia-204 H2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SPRUCE BIOSCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income $11.4 million.

Period: the third quarter ended September 30, 2022
Net income: $11.4 million
Result: reported results

Exact text from the filing

Net loss for the three and nine months ended September 30, 2022 was $11.4 million and $35.0 million, respectively, compared to $11.4 million and $33.1 million, respectively, for the same periods in 2021.

View on SEC.gov

10 earnings releases filed in the last 30 days. Browse all earnings releases →

SPRUCE BIOSCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000950170-22-024479

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.